FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer

HER2-positive breast cancer (BC) is an aggressive subtype that affects 20–25% of BC patients. For these patients, neoadjuvant therapy is a good option that targets a pathological complete response (pCR) and more breast-conserving surgery. In effect, the outcomes of patients with HER2-positive BC hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaibar, María, Novillo, Apolonia, Romero-Lorca, Alicia, Malón, Diego, Antón, Beatriz, Moreno, Amalia, Fernández-Santander, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875219/
https://www.ncbi.nlm.nih.gov/pubmed/35213975
http://dx.doi.org/10.3390/pharmaceutics14020242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875219/
https://www.ncbi.nlm.nih.gov/pubmed/35213975
http://dx.doi.org/10.3390/pharmaceutics14020242

Ejemplares similares